Filing Details

Accession Number:
0001179110-13-004840
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-03-11 17:48:32
Reporting Period:
2013-03-07
Filing Date:
2013-03-11
Accepted Time:
2013-03-11 17:48:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1225509 M Suzanne Shema C/O Onyx Pharmaceuticals, Inc.
249 E. Grand Ave.
South San Francisco CA 94080
Evp, Gc And Corp. Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-03-07 1,215 $32.07 35,048 No 4 M Direct
Common Stock Acquisiton 2013-03-07 657 $30.28 35,705 No 4 M Direct
Common Stock Acquisiton 2013-03-07 802 $35.18 36,507 No 4 M Direct
Common Stock Acquisiton 2013-03-07 584 $37.68 37,091 No 4 M Direct
Common Stock Acquisiton 2013-03-07 796 $37.68 37,887 No 4 M Direct
Common Stock Disposition 2013-03-07 4,054 $79.72 33,833 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-03-07 1,215 $0.00 1,215 $32.07
Common Stock Stock Option (Right to Buy) Disposition 2013-03-07 657 $0.00 657 $30.28
Common Stock Stock Option (Right to Buy) Disposition 2013-03-07 802 $0.00 802 $35.18
Common Stock Stock Option (Right to Buy) Disposition 2013-03-07 584 $0.00 584 $37.68
Common Stock Stock Option (Right to Buy) Disposition 2013-03-07 796 $0.00 796 $37.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
19,758 2019-08-31 No 4 M Direct
8,531 2020-03-31 No 4 M Direct
20,053 2021-03-31 No 4 M Direct
21,583 2022-03-29 No 4 M Direct
29,445 2022-03-29 No 4 M Direct
Footnotes
  1. 25% of the shares subject to the option become exercisable one year following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 36 months for a total vesting schedule of 48 months.
  2. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
  3. The shares vest monthly from the date of grant at a rate of 1/48th per month.
  4. Shares sold pursuant to a 10b5-1 Plan.